All Updates

All Updates

icon
Filter
Partnerships
Fulgent Pharma and Moffitt Cancer Center partner to advance personalized cancer therapies
Precision Medicine
May 15, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Yesterday
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Yesterday
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Yesterday
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Yesterday
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Yesterday
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Yesterday
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Yesterday
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Yesterday
Precision Medicine

Precision Medicine

May 15, 2024

Fulgent Pharma and Moffitt Cancer Center partner to advance personalized cancer therapies

Partnerships

  • Fulgent Pharma has partnered with Moffitt Cancer Center to accelerate the development of personalized cancer therapies.

  • The collaboration grants Moffitt priority access to Fulgent's resources and know-how to expedite the advancement of Fulgent's clinical pipeline. This includes prioritizing clinical trials, enhancing patient screening, and data sharing. Together, the companies aim to develop personalized cancer treatments using Moffitt's scientific expertise and Fulgent's nanotherapeutic drug development platform.

  • Fulgent Pharma is a clinical-stage pharmaceutical company specializing in the development and commercialization of novel cancer therapies. The company is a subsidiary of the nanobiotechnology company Fulgent Genetics. Fulgent Pharma focuses on creating treatments through technologies such as nanoencapsulation to improve the delivery and efficacy of cancer drugs. Its pipeline includes targeted therapies for various cancers, such as breast, lung, ovarian, colon, and pancreatic.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.